The clinical practice guidelines for NAFLD recommend that PCPs should consider screening patients who are at high risk for NAFLD, specifically those with metabolic risk factors such as obesity and diabetes [21,22], or be aware of the higher risk of NAFLD in such patients [9,49], while diabetes guidelines recommend evaluating high-risk patients for NAFLD and fibrosis when they present with elevated ALT levels or hepatic steatosis on a US [50]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.